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Human dermal fibroblasts are actively involved in
inflammatory processes. These resident cells are not
only responsible for the production and maintenance
of the connective tissue matrix, but are also able to
activate the overlying epidermal cells and contiguous
endothelial cells, as well as to attract and activate infil-
trating leucocytes. Their ability to take part in cellular
communication is, at least in part, determined by the
expression of adhesion molecules, cytokines and
cytokine receptors. Human dermal fibroblasts are able
to express the major histocompatibility complex
(MHC) class I and II molecules,1,2 and b 1 integrins and
the intercellular adhesion molecule (ICAM-)1.3,4 It has
furthermore been reported that fibroblasts produce
interleukin(IL-)1 isoforms, IL-6, IL-8, monocyte
chemotactic protein (MCP-)1, leukaemia inhibitory
factor (LIF), platelet-derived growth factors (PDGF)
and the colony stimulating factors (CSF).5–11 Human
dermal fibroblasts also express receptors (R) for IL-1,
tumour necrosis factor (TNF), the interferons (IFN),
PDGF and the transforming growth factors (TGF).12–16
It is important to note that cytokine receptors often
reflect the activation state of cells and are involved in
the regulation of cytokine activity. Most receptors
occur, apart from membrane forms, in soluble forms.17
Soluble receptors either antagonize cytokine activity by
scavenging, neutralization and prevention of extravas-
cular escape of cytokines, or agonize cytokine activity
by increase of persistence and chaperoning of
cytokines.18 The activity of cytokines is therefore, at
least in part, the result of both the expression of
cytokines as well as their receptors.
Active participation of dermal fibroblasts in the
inflammatory mechanisms of psoriasis is evidenced by
their hyperactive state in vitro. Psoriatic fibroblasts pro-
duce elevated amounts of superoxide anion, PDGF-BB
and IL-1b , express elevated levels of surface proteases
(e.g. exoaminopeptidases and CD26), protein kinase C
activity and PDGFRb , and show an altered response to
serum factors, growth factors and several therapeu-
tics.19–25 Fibroblasts are furthermore a potential source for
the locally produced bioactive IL-6 in psoriasis.26–27 We
observed that psoriatic fibroblasts express an increased
production of IL-6 in vitro (see previous paper, pp 70–79).
80 CYTOKINE, Vol. 8, No. 1 (January), 1996: pp 80–88
EXPRESSION OF CYTOKINES AND THEIR
RECEPTORS BY PSORIATIC FIBROBLASTS.
II. DECREASED TNF RECEPTOR EXPRESSION
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Psoriatic fibroblasts produce enhanced amounts of IL-6 in vitro. This state of activation may
reflect an altered expression of cytokine receptors, involved in auto/paracrine induction of
IL-6. Cultures of dermal fibroblasts derived from lesional psoriatic (PP) and normal control
(NN) skin were therefore analysed for their ability to bind biotinylated recombinant human
cytokines using flow cytometry. PP and NN fibroblasts bound negligible amounts of IL-1a
and IL-1b , but clearly bound IL-4, IL-6 and TNF-a . Serum upregulated the number of NN
fibroblasts which bound TNF-a , and to a lesser extent IL-6, but not the number of binding
sites per cell. In contrast, this upregulation was significantly less in PP fibroblasts. This was
not a result of differences in growth characteristics, receptor occupancy or an inability of
stimulated PP fibroblasts to bind TNF-a . Immunocytochemistry of cells grown on slides
showed that the TNF receptor type 1 (TNFR1, p55) was the predominant receptor in NN
fibroblasts and was localized to the nucleus and cytoplasma. The expression of TNFR1 was
clearly decreased in PP fibroblasts, which confirmed the binding studies. A slow and serum-
induced shedding of TNFR1 was observed, but not of the TNFR2 (p75), in both types
of fibroblasts. Confluent multi-passaged PP fibroblasts display both a decreased TNFR
expression as well as an enhanced IL-6 production under serum conditions. These inherent
abnormalities of PP fibroblasts imply the involvement of dermal fibroblasts in the mainten-
ance of chronic inflammation in psoriasis.
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IL-6 links cutaneous inflammation and keratinocyte
hyperproliferation in psoriasis. Moreover, in a mouse
model, a psoriasiform inflammatory reaction was pre-
ceded by an increase in the endogeneous IL-6 produc-
tion in the skin.28 The present study was conducted to
investigate whether the enhanced fibroblast-derived IL-
6 activity in psoriasis was associated with an altered recep-
tor expression. We therefore analysed the expression of
binding sites for IL-1a , IL-1b , IL-4, IL-6 and TNF-a , and
the production of biologically active IL-6, as well as the
IL-6 related cytokines IL-1 and TNF-a , of early passages
of fibroblast cultures derived from lesional psoriatic (PP)
and normal control (NN) skin. Experiments were per-
formed using a low and high-calcium basal medium and
stimuli such as cytokines and serum.
RESULTS
PP and NN fibroblasts clearly bind IL-4, IL-6 and
TNF-a , but not IL-1a or IL-1b
Cultures of NN fibroblasts hardly bound biotiny-
lated recombinant human IL-1a or IL-1b , even after
stimulation with phorbol myristate acetate (PMA),
lipopolysaccharide (LPS), or the recombinant human
cytokines IL-1b , TNF-a , or IFN-g , as shown in Figure
1. Fibroblasts positive for binding with IL-4, IL-6 and
TNF-a were clearly detectable and the binding of the
former two cytokines was upregulated in stimulated
fibroblasts. For instance, IL-1b -treated fibroblasts
showed a substantially increased binding of IL-6, and
IFN-g -treated fibroblasts displayed increased binding
of IL-4. PP fibroblasts also clearly bound IL-4, IL-6
and TNF-a (Fig. 2), but negligible amounts of IL-1a
and IL-1b (not shown). The binding of IL-4, IL-6 and
TNF-a by both types of fibroblasts could be modulated
by the use of different culture conditions, as shown in
Figure 2. The binding of these cytokines was lower,
although with a varying degree, using a high-calcium
(1.05 mM), serum-free medium (a 1:1 ratio of
F10:DMEM) when compared to a low-calcium (0.15
mM), serum-free medium (KBM/unsupplemented
MCDB 153) (second versus first bars, Fig. 2). An
increased binding was observed using fetal calf serum
(FCS)-supplemented (5% v/v) medium (third versus
second bars, Fig. 2). The observation that PP fibroblasts
were able to bind more IL-4 than NN fibroblasts after
a 24 h period under serum conditions was not statisti-
cally significant.
PP fibroblasts express a decreased binding of 
TNF-a under serum conditions
We observed that the binding of IL-6 and TNF-a
by NN fibroblasts, but not the other cytokines, increased
when cells were cultured for up to 72 h in the presence
of FCS. Serum upregulated the mean percentage of NN
fibroblasts able to bind TNF-a (Fig. 3A), but not the
number of TNF-a binding sites per cell, as indicated by
the relative fluorescence intensities of the same cell
samples (Fig. 3B). Culturing PP fibroblasts, however,
for up to 72 h under serum conditions resulted in a
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Figure 1. The binding of cytokines by fibroblasts.
Subconfluent NN fibroblast cultures were incubated with a high-calcium medium contain-
ing 5% FCS for 24 h and analysed for their ability to bind the cytokines mentioned on the
X-axis using flow cytometry, as described in Materials and Methods. The stimuli used were
50 ng/ml PMA, 10 m g/ml LPS, 100 U/ml IL-1b , 100 U/ml TNF-a and 100 U/ml IFN-g , added
the last 14 h of the 24 h incubation. Results are expressed as the percentage of positive cells
after labelling with biotinylated recombinant human cytokines of a representative experi-
ment. The experiment was performed in duplo.
significantly lower number of fibroblasts that bound
TNF-a when compared to NN fibroblasts (P , 0.03, Fig.
3A, and Fig. 5A and B). To a lesser extent the same was
true for IL-6 (not shown). The increased binding of
TNF-a by NN fibroblasts under serum conditions cor-
related with a decrease in the percentage of cycling cells.
The decreased binding of TNF-a by PP fibroblasts, as
mentioned above, is, however, not a result of differences
in growth characteristics between PP and NN fibro-
blasts, as checked by cell counts (data not shown) and
the percentage of cycling cells (G2/M phase) (Fig. 4).
Furthermore, TNF-a binding sites of PP fibroblasts
were not occupied with endogenously produced TNF
molecules in vitro, as evidenced by the observation that
fibroblasts did not produce TNF-a and by acid strip-
ping of fibroblasts prior to flow cytometry (Fig. 5C).
Stimulated PP fibroblasts were also still able to up-
regulate binding of TNF-a (Fig. 5D).
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Figure 2. Calcium and serum modulate the binding of cytokines by PP and NN fibroblasts.
PP and NN fibroblasts (both n 5 10) were incubated with a low or high-calcium, serum-free
medium, or a high-calcium medium containing 5% FCS for 24 h, and analysed for their abil-
ity to bind cytokines using flow cytometry. Results are expressed as the mean 6 SEM per-
centage of positive cells.
Figure 3. PP fibroblasts express decreased binding of TNF-a under
serum conditions.
PP and NN fibroblasts (both n 5 10) were analysed using flow
cytometry for the percentage of cells which bind TNF-a (A) and the
relative number of TNF-a binding sites per cell (B), after culture in
a high-calcium, serum-free medium for 24 h, or a high-calcium
medium containing 5% FCS for 24 or 72 h. Percentages of positive
cells and the signal to noise ratios are presented as mean 6 SEM.
The P value indicates a significant difference between PP and NN
fibroblasts.
Figure 4. Growth characteristics of PP and NN fibroblasts.
Cell cycle analysis was performed on PP and NN fibroblasts (both
n 5 8) cultured in a low or high-calcium, serum-free medium for 24
h, or a high-calcium medium containing 5% FCS for 24 or 72 h. Cells
were fixed, the DNA was labelled with propidium iodide and
analysed using flow cytometry, as described in Materials and
Methods. Results are expressed as mean 6 SEM percentage of
cycling cells (G2/M-phase).
Shedding of TNFR1 (p55) does not explain the
decreased expression of this receptor in PP fibroblasts
Immunocytochemical staining of cells grown on
slides showed that NN fibroblasts cultured under serum
conditions clearly express the TNFR1 (the p55 recep-
tor form), but only low levels of the TNFR2 (the p75
form) (Fig. 6). The TNFR1 was predominantly local-
ized in the nucleus and to a lesser extent in the cyto-
plasm. In contrast, PP fibroblasts expressed very low
levels of immunoreactive TNFR1.
Fibroblast-conditioned media contained the sol-
uble TNFR1 as well as the soluble TNFR2, as measured
with specific sandwich ELISA (Table 1). The shedding
of TNFR1 was enhanced by serum and was maximal at
72 h. The presence of soluble TNFR2 was, however,
almost negligible, which confirmed the immunocyto-
chemical stainings. The amounts of soluble TNFR pre-
sent in the supernatants of PP and NN fibroblast
cultures were similar and do not explain the differences
found for membrane-bound TNFR between PP and NN
fibroblasts.
PP fibroblasts co-express decreased TNFR levels and
an enhanced IL-6 production
The supernatants of the fibroblast cultures con-
tained substantial amounts of biologically active IL-6
(Table 2). Both types of fibroblasts did not produce bio-
logically active IL-1 or TNF-a . The serum-induced
increase in IL-6 production correlated with the increase
in binding of TNF-a in NN fibroblasts. PP fibroblasts,
however, expressed an enhanced production of IL-6
together with a decreased binding of TNF-a .
DISCUSSION
This is the first study in which the expression of
cytokine receptors on lesional psoriatic dermal fibro-
blasts was investigated. We observed that PP and NN
fibroblasts expressed negligible IL-1 binding sites (Figs
1 and 2). Epidermal cells, used as control cells, were pos-
itive for binding of IL-1a and IL-1b which validated our
methodology (not shown). Qwarnström and colleagues
found that cultures of human gingival fibroblasts did
express binding sites for both the IL-1a and IL-1b iso-
form.12 Apart from the possibility that biotinylation of
IL-1 affects receptor binding, as Qwarnström and col-
leagues used iodinated IL-1, tissue-specific differences
cannot be excluded. For example, the production of bio-
logically active IL-1 can be triggered in gingival fibro-
blasts,29 but not in dermal fibroblasts (see previous
paper, pp 70–79). Our finding of negligible expression
of IL-1 binding sites on dermal fibroblasts does not nec-
essarily imply unresponsiveness of these cells to IL-1.
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Figure 5. PP fibroblasts do not express occupied TNF-a binding sites and up-regulate the binding of TNF-a
after stimulation.
Fluorescence intensities using biotinylated TNF-a are given of NN (A) and PP fibroblasts (B, C and D) (both
n 5 3) cultured in a high-calcium medium containing 5% FCS for 24 or 72 h. A and B illustrate the decreased
binding of TNF- a by PP fibroblasts. C shows the effect of acid stripping, and D the effect of a 50 ng/ml PMA
stimulus for 14 h on PP fibroblasts. See Materials and Methods for details. Shown are a representative NN and
PP fibroblast culture.
Only a few IL-1R type I molecules per cell are sufficient
for an IL-1 mediated response.30 This is confirmed by
our novel finding that IL-1b stimulation of fibroblasts
resulted in substantially upregulated binding of IL-6.
The IL-4R has been demonstrated on gingival fibro-
blasts,31 while dermal fibroblasts have been shown to
give a biological response to exogenous recombinant
human IL-4 and IL-6.32,33 In this report we provide evi-
dence that human dermal fibroblasts express binding
sites for IL-4 and IL-6. Our observation that fibroblasts
bind TNF-a confirms the findings by Berman and 
others.14 The expression of cytokine binding sites by PP
and NN fibroblasts was modulated by the use of differ-
ent culture conditions. Calcium seemed to lower the
expression of binding sites for IL-4, IL-6 and TNF-a
(Fig. 2). However, extracellular calcium, using similar
concentrations enhanced the IL-1R levels in cultured
human keratinocytes.34 This probably reflects cell-type
specific differences. Addition of FCS resulted in
increased binding of IL-4, IL-6 and TNF-a . This
increased binding initially parallelled the induction of
fibroblast proliferation (third versus second bars, Fig.
4), implying enhanced responsiveness to cytokines of
fibroblasts starting to proliferate.
Differences in cytokine binding between PP and
NN fibroblasts became evident when confluent cultures
were analysed. Culturing of PP fibroblasts for up to 72
h in the presence of serum did not affect the number of
cells which bound TNF-a . This is in sharp contrast with
the serum-upregulated binding of TNF-a by NN fibro-
blasts (Fig. 3A). The number of TNF-a binding sites per
cell, however, did not increase under serum conditions
in either NN or PP fibroblasts (Fig. 3B). As the expres-
sion of cytokine receptors may directly correlate with
the fraction of cells in cycle,35 we analysed the growth
characteristics of PP and NN fibroblasts. It is important
to note that studies on the proliferation rates of PP and
NN fibroblasts in response to FCS are inconsistent.23,24
Similar proliferation rates for both types of fibroblasts
as well as a hyperproliferative state of PP fibroblasts
have both been reported. In our study, however, there
were no significant differences in cell counts and the
percentage of cycling cells, although the percentage of
proliferating cells was somewhat higher in confluent
PP fibroblasts (72 h under serum conditions) when
compared to NN fibroblasts (Fig. 4). Furthermore,
the TNF-a binding sites of PP fibroblasts were not occu-
pied with endogenously produced TNF-a (Fig. 5C), and
PP fibroblasts did also not lose their ability to upregu-
late the binding of TNF-a (Fig. 5D).
TNF-a can bind to two types of TNFR, TNFR1 and
TNFR2, which are both active in signal transduction
and are responsible for nonredundant TNF activities.36
Most immunomodulatory effects of TNF-a on fibro-
blasts are mediated by TNFR1. Immunocytochemistry
showed that the expression of TNFR1 was clearly
decreased in PP fibroblasts (Fig. 6), which is in line with
the binding experiments (Figs 5A and B). These stain-
ing results imply that the decreased binding of TNF-a
by PP fibroblasts is not due solely to an altered affinity
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Figure 6. PP fibroblasts express decreased levels of TNFR1.
NN (A, C, E and F) and PP fibroblasts (B and D) were stained with
the anti-TNFR1 antibody htr-9 (A and B) and the anti-TNFR2 anti-
body utr-1 (C and D). Staining of NN fibroblasts with mouse IgG1
(E) and the antibody 5B5 (F) were used as controls. Cells were
grown on slides in a high-calcium medium containing 5% FCS to
confluence, fixed and stained, as described in Materials and
Methods. Shown are a representative PP and NN fibroblast culture.
The experiment was performed in duplo. Magnification: 3153.
TABLE 1. Shedding of TNFR by PP and NN fibroblasts
Psoriasis Normal control
TNFR1 TNFR2 TNFR1 TNFR2
pg/ml pg/ml pg/ml pg/ml
Culture condition
24 h high Ca21 medium 8 ,5 14 ,5
24 h high Ca21 medium
with serum 29 8 30 6
72 h high Ca21 medium
with serum 120 10 100 7
Supernatants of PP and NN fibroblasts were analysed for soluble TNFR1 and
TNFR2 by ELISA. Fibroblasts were cultured in a high-calcium (Ca21), serum-
free medium for 24 h, or a high Ca21 medium containing 5% FCS for 24 or 72
h. Results are given of a representative PP and NN fibroblast culture (both 
n 5 3), and expressed in pg/ml.
of TNFRs for the TNF-a , but may merely reflect a
decreased expression of TNFR 1. Both types of recep-
tors are shed either by protein kinase C dependent pro-
teolysis (induced by PMA) or by protein kinase C
independent proteolysis (induced by IL-1 and IL-4).37,38
We observed that serum enhanced shedding of TNFR1
by both types of fibroblasts, which may be due to serum-
induced endogenous protein kinase C activity. The
kinetics of the shedding was slow (Table 1). A similar
slow process of release of soluble TNFR was also found
using PBMC.39 Amounts of soluble TNFR2 in the
supernatants were very low but still detectable, being
in line with the low expression of this receptor found
with immunocytochemistry. Shedding, being similar for
both types of fibroblasts, does not explain the decreased
TNFR expression by PP fibroblasts. Furthermore, the
observation that PP fibroblasts express negligible intra-
cellular levels of immunoreactive TNFR does not 
support rapid TNFR upregulation and subsequent
internalization of the receptors by these cells. Thus, at
the moment, we speculate that PP fibroblasts exhibit a
deficiency in serum-induced TNFR upregulation. This
is in line with an elevated synthesis of extracellular
matrix proteins and an increased expression of
PDGFRb , which have been considered as intrinsic phe-
notypic abnormalities of multi-passaged PP fibro-
blasts.20,40 In vivo, PP fibroblasts also express elevated
levels of PDGFRb ,41 and show an increased biological
response to PDGF in vitro.42 Although factors deter-
mining the responsiveness to TNF-a are not fully
known yet, it has been shown that fibroblasts derived
from affected skin from scleroderma patients do not
respond to TNF-a in upregulating TNFR2 mRNA 
levels. Scleroderma and normal fibroblasts do not dif-
fer at the TNFR protein level, but scleroderma fibro-
blasts constitutively contain TNFR1 and TNFR2
mRNA, whereas normal fibroblasts constitutively
express mainly TNFR 1 mRNA.14
TNF- a has mitogenic activity and many
immunomodulatory activities on human dermal fibro-
blasts.43 For example, TNF-a upregulates the expres-
sion of enzymes, cytokines (e.g. IL-1, IL-6 and IL-8),
adhesion and MHC molecules, and stimulates chemo-
taxis. One would expect that the decreased TNFR
expression by PP fibroblasts affects the inflammatory
response of these cells to TNF-a . However, several
arguments do not favour this hypothesis. First, we only
observed a decreased TNFR expression in response to
factors present in FCS, not to other stimulating agents
(e.g. PMA, Fig. 5D). Second, PP fibroblasts co-
expressed a decreased binding of TNF-a together with
an increased production of IL-6 in contrast to NN
fibroblasts (Table 2). Third, the degree of receptor den-
sity does not always correlate with TNF-a responsive-
ness,13 and the biological actions of TNF-a are not
always preceded by receptor internalization.44 More-
over, using a murine model, subcutaneous injection of
a combination of lithium chloride (a drug used to treat
manic depressive disease and known to trigger or aggre-
vate psoriasis as a side effect) and TNF-a induced a pso-
riasiform inflammatory reaction via an increase in 
the endogeneous IL-6 production in the skin.28
Immunohistochemistry of biopsies of human skin also
showed that the in vivo expression of TNFR is altered
in the dermal compartment of psoriatic lesions.45 The
decreased TNFR expression by PP fibroblasts demon-
strated in vitro suggests that dermal fibroblasts are, at
least in part, involved in maintaining the in vivo milieu
characteristic of psoriatic lesions.
MATERIALS AND METHODS
Patients and controls
Ten patients with active plaque-type psoriasis and ten
healthy volunteers, undergoing plastic surgery, were studied
as described (see previous paper, p. 76).
Culturing of fibroblasts
Split-skin specimens from PP and NN skin were used to
establish fibroblast cultures (see previous paper, p. 76). For
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TABLE 2. PP fibroblasts co-express decreased binding of TNF-a and increased IL-6
production
Psoriasis Normal control
Binding TNF-a IL-6 production Binding TNF-a IL-6 production
% U/105 cells % U/105 cells
Culture condition
24 h high Ca21 medium 1 33 16 11
24 h high Ca21 medium
with serum 0 258 11 6
72 h high Ca21 medium
with serum 1 300 40 13
The percentage of PP and NN fibroblasts which bind TNF-a and the corresponding production of IL-6 in U/105
cells were analysed using flow cytometry and the B9 bioassay, respectively. Fibroblasts were cultured in a high-
calcium (Ca21), serum-free medium for 24 h, or a high Ca21 medium containing 5% FCS for 24 or 72 h. The
results are shown of a representative PP and NN fibroblast culture (both n 5 5).
experiments, fibroblasts of passage no. 2 to 6 were used. Cells
were seeded in 175 cm2 flasks and grown to subconfluence
using Dulbecco’s modification of Eagle’s medium (DMEM:
Gibco Ltd., Paisley, Scotland) supplemented with 10% FCS
(Gibco), 100 U/ml penicillin and 100 m g/ml streptomycin. Cells
were subsequently rinsed twice with PBS and incubated for 24
or 72 h with one of the following test media: (1) a low-calcium
(0.15 mM), serum-free medium (keratinocyte basal medium,
KBM/unsupplemented MCDB 153: Clonetics, San Diego,
CA); (2) a high-calcium (1.05 mM), serum-free medium con-
sisting of Ham’s F10 (Gibco) and DMEM in a ratio of 1:1 sup-
plemented with antibiotics; (3) the high-calcium medium
supplemented with 5% FCS. The stimuli used were 50 ng/ml
PMA (Sigma Chemie, Bornem, Belgium), 10 m g/ml LPS
(Escherichia coli 026:B6, Difco Laboratories, Detroit, MI),
100 U/ml recombinant human IL-1b (UBI, Lake Placid, NY),
100 U/ml TNF-a (UBI) and 100 U/ml IFN-g (Boehringer
Ingelheim, Germany), added the last 14 h of the 24 h incu-
bation with the serum-containing medium. Supernatants were
collected by centrifugation and stored at 280°C.
Quantitation of cytokine binding sites
Fibroblasts were collected (0.025% trypsin and 0.1%
EDTA), trypsinization was stopped with 100 m g/ml trypsin
inhibitor (Sigma), and cells were extensively washed with
PBS. Viability was determined by trypan blue exclusion and
always exceeded 95%. The mild trypsinization procedure did
not affect the binding of cytokines, as checked by the use of
cells collected with EDTA only. The labelling was performed
according to the protocol supplied by the manufacturer. In
short, 5 3 104 cells were incubated for 1 h at 4°C with approx-
imately 180 ng biotinylated recombinant human IL-1a ,
IL-1b , IL-4, IL-6 or TNF-a (all purchased from R&D Systems,
Minneapolis, MN) using 12 3 75 mm round bottom, poly-
styrene tubes (Becton Dickinson). Unbound cytokines were
removed by two rinses with PBS containing 0.1% bovine
serum albumin (BSA) (washing buffer). Next, cells were incu-
bated for 30 min at 4°C in the dark with avidin-FlTC (R&D
Systems), used in combination with IL-1 labelling, or strep-
tavidin-phycoerythrin (Becton Dickinson) used in combina-
tion with the other cytokines. Subsequently, cells were rinsed
twice, resuspended in washing buffer and used for flow-
cytometry. Peripheral blood mononuclear cells and the U937
promonocytic cell line were used as positive controls for the
expression of cytokine binding sites (not shown). Analysis was
conducted using the FACScanC and LysisC software programs
(Becton Dickinson). The frequency of cells positive for the
binding of cytokines was determined using single-parameter
fluorescence histograms and corrected for aspecific staining
of the second step (background). The results are presented
either as histograms or as mean 6 SEM percentage of posi-
tive cells. The relative number of binding sites per cell was
estimated by the relative signal-to-noise values.46
To correct for the number of receptors already occupied
with cytokines in vitro, the receptor-bound cytokines were
stripped in some experiments before labelling. Briefly, cells
were suspended in the first stripping buffer (10 mM
Na3C6H5O7·2H2O and 0.14 M NaCl, pH 4.0) and kept on ice
for 20 sec.47 The stripping was stopped by adding medium con-
taining Hepes and BSA. Cells were rinsed twice with wash-
ing buffer before incubating the cells with the second strip-
ping buffer (0.1 M glycine-HCl, pH 3.0) for 2 min on ice.12 The
stripping was stopped and cells were washed twice before
labeling. The efficiency of the procedure was checked by strip-
ping cells after incubation with biotinylated cytokines. This
reduced the signal intensity to background levels.
Cell cycle analysis
To analyse the cell cycle, cells were labelled with propid-
ium iodide. Briefly, 5 3 104 fibroblasts were fixed with ice-cold
70% ethanol on ice for 15 min. Subsequently, cells were
collected by centrifugation (1000 3 g, 5 min) and treated
with 1 U/ml DNAse-free RNAse A (Boehringer Mannheim,
Germany) for 30 min at 37°C. Finally, cells were centrifuged
and resuspended in 100 m l of 50 m g/ml propidium iodide
(Becton Dickinson), after which flow cytometry was performed.
As a negative control, cells were treated with 100 U/ml DNAse
(Sigma Chemical Co., St. Louis, MO) instead of RNAse.
ELISA for soluble TNFR
Soluble TNFR1 and TNFR2 were measured with a
sandwich ELISA using the monoclonal antibodies MR1-1,
MR2-2 and rabbit anti-soluble TNFR antiserum.39
Bioassays for IL-1, IL-6 and TNF-a
IL-1, IL-6 and TNF-a activities were measured using the
B9, D10 and WEHI assay, respectively, as described else-
where.48–50
Immunocytochemistry
PP and NN fibroblasts were grown on slides, fixed with
a 1:1 methanol:aceton solution for 15 min at room tempera-
ture and stained with the mouse anti-human TNFR mono-
clonal IgG1 antibodies htr-9 and utr-1 (Dr M. Brockhaus,
Hoffmann-La Roche, Basel, Switzerland), at 10 m g/ml, using
the supersensitive alkaline phosphatase kit (Biogenex, San
Ramon, CA) to study the expression of TNFR1 and TNFR2,
respectively.51 Cells were counterstained with haematoxylin.
The negative controls comprised staining with purified mouse
IgG1 (Becton Dickinson) at 10 m g/ml and omitting the first
and second steps. Staining with 5B5 (Dako, Glostrup,
Denmark), a purified mouse monoclonal IgG1 antibody
directed against human prolyl 4-hydroxylase, which is
specifically expressed by fibroblasts, at 2 m g/ml, served as a
positive control. Stainings were evaluated using a standard
Zeiss 16 microscope (Carl Zeiss, Oberkochen, Germany).
Statistical analysis
Flow cytometry, ELISA and bioassay results were
analysed with the Wilcoxon Rank Sum Test using STATATM
(Computing Resource Center, Los Angeles, CA). P values
,0.05 were considered statistically significant.
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